, Volume 46, Issue 2, pp 147–163 | Cite as

Current and future challenges in HCV: insights from an Italian experts panel

  • Massimo Andreoni
  • Sergio Babudieri
  • Savino Bruno
  • Massimo Colombo
  • Anna L. Zignego
  • Vito Di Marco
  • Giovanni Di Perri
  • Carlo F. Perno
  • Massimo Puoti
  • Gloria Taliani
  • Erica Villa
  • Antonio Craxì



The recent availability of direct acting antiviral drugs (DAAs) has drastically changed hepatitis C virus (HCV) treatment scenarios, due to the exceedingly high rates of sustained virological response (SVR) and excellent tolerability allowing for treatment at all disease stages.


A panel of Italian experts was convened twice, in November 2016 and January 2017, to provide further support on some open issues and provide guidance for personalized HCV care, also in light of forthcoming regimens.

Results and conclusions

Treatment recommendations issued by international and national liver societies to guide clinicians in the management of HCV infection are constantly updated due to accumulating new data. Such recommendations may not be applicable to all healthcare settings for a variety of reasons. Moreover, some gaps still remain and the spectrum of patients to be treated is also evolving.


HCV Treatment DAAs Comorbidities 



Editorial assistance for manuscript preparation was provided by HPS, Health Publishing & Services, Srl, Italy. This work was funded by an unrestricted grant by MSD Italia Srl. The sponsor had no role in selecting the participants, reviewing the literature, defining recommendations, drafting or reviewing the paper, or in the decision to submit the manuscript for publication. All views expressed are solely those of the authors.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Webster DP, Klenerman P, Dusheiko GM. Hepatitis C. Lancet. 2015;385:1124–35. Scholar
  2. 2.
  3. 3.
    Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol. 2007;13:2436–41.PubMedPubMedCentralCrossRefGoogle Scholar
  4. 4.
    Global Burden Of Hepatitis CWG. Global burden of disease (GBD) for hepatitis C. J Clin Pharmacol. 2004;44:20–9. Scholar
  5. 5.
    Messina JP, Pigott DM, Golding N, Duda KA, Brownstein JS, Weiss DJ, et al. The global distribution of Crimean-Congo hemorrhagic fever. Trans R Soc Trop Med Hyg. 2015;109:503–13. Scholar
  6. 6.
    Negro F, Forton D, Craxi A, Sulkowski MS, Feld JJ, Manns MP. Extrahepatic morbidity and mortality of chronic hepatitis C. Gastroenterology. 2015;149:1345–60. Scholar
  7. 7.
    Vigano M, Colombo M. Extrahepatic Manifestations of Hepatitis C Virus. Gastroenterol Clin North Am. 2015;44:775–91. Scholar
  8. 8.
    AISF. Documento di indirizzo dell’Associazione Italiana per lo Studio delFegato per l’uso razionale di antivirali diretti di seconda generazione nellecategorie di pazienti affetti da epatite C cronica ammessi alla rimborsabil-ità in Italia. Available at Accessed 30 Oct 2017.
  9. 9.
    European Association for Study of L. EASL recommendations on treatment of hepatitis C 2015. J Hepatol. 2015;63:199–236. Scholar
  10. 10.
    Panel AIHG. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology. 2015;62:932–54. Scholar
  11. 11.
    Soriano V, Benitez-Gutierrez L, Arias A, Carrasco I, Barreiro P, Pena JM, et al. Evaluation of sofosbuvir, velpatasvir plus voxilaprevir as fixed-dose co-formulation for treating hepatitis C. Expert Opin Drug Metab Toxicol. 2017;13:1015–22. Scholar
  12. 12.
    Gane E, Poordad F, Wang S, Asatryan A, Kwo PY, Lalezari J, et al. High efficacy of ABT-493 and ABT-530 treatment in patients with HCV genotype 1 or 3 infection and compensated cirrhosis. Gastroenterology. 2016;151:651–659e1. Scholar
  13. 13.
    Foster GR, Afdhal N, Roberts SK, Brau N, Gane EJ, Pianko S, et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med. 2015;373:2608–17. Scholar
  14. 14.
    Zeuzem S, Ghalib R, Reddy KR, Pockros PJ, Ben Ari Z, Zhao Y, et al. Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med. 2015;163:1–13. Scholar
  15. 15.
    Alric L, Bonnet D. Grazoprevir + elbasvir for the treatment of hepatitis C virus infection. Expert Opin Pharmacother. 2016;17:735–42. Scholar
  16. 16.
    Zeuzem S, Feld JJ, Wang S, Bourlière M, Wedemeyer H, Gane EJ. ENDURANCE-1: efficacy and Safety of 8-versus 12-week treatment with ABT-493/ABT-530 in patients with chronic HCV genotype 1 infection. Hepatology. 2016;64:132A.Google Scholar
  17. 17.
    Asselah T, Hezode C, Zadeikis N, Elkhashab M, Colombo M. ENDURANCE-4: efficacy and safety of ABT-493/ABT-530 treatment in patients with chronic HCV genotype 4, 5, or 6 infection. Hepatology. 2016;64:63A.Google Scholar
  18. 18.
    Wyles DL, Poordad F, Wang S, Alric L, Felizarta F, Kwo PY. SURVEYOR-II, Part 3: efficacy and safety of ABT-493/ABT-530 in patients with hepatitis C virus genotype 3 infection with prior treatment experience and/or cirrhosis. Hepatology. 2016;64:62A.Google Scholar
  19. 19.
    European Association for the Study of the Liver. Electronic address eee. EASL recommendations on treatment of hepatitis C 2016. J Hepatol. 2017;66:153–94. Scholar
  20. 20.
    Coburn CA, Meinke PT, Chang W, Fandozzi CM, Graham DJ, Hu B, et al. Discovery of MK-8742: an HCV NS5A inhibitor with broad genotype activity. ChemMedChem. 2013;8:1930–40. Scholar
  21. 21.
    Harper S, McCauley JA, Rudd MT, Ferrara M, DiFilippo M, Crescenzi B, et al. Discovery of MK-5172, a macrocyclic hepatitis C virus NS3/4a protease inhibitor. ACS Med Chem Lett. 2012;3:332–6. Scholar
  22. 22.
    Summa V, Ludmerer SW, McCauley JA, Fandozzi C, Burlein C, Claudio G, et al. MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants. Antimicrob Agents Chemother. 2012;56:4161–7. Scholar
  23. 23.
    Kirby BJ, Taylor J, Stamm LM. Evaluation of transporter and cytochrome P450-mediated drug-drug interactions with the pan genotypic HCV NS3/4A protease inhibitor voxilaprevir (GS-9857) or sofosbuvir/velpatasvir/voxilaprevir and phenotypic probe drugs. In: 17th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy. June 8–10, 2016, Washington, DC. (Abstract # O24 and O25). 2016.Google Scholar
  24. 24.
    Mogalian E. Drug-drug interaction studies between hepatitis C virus antivirals sofosbuvir and velpatasvir and HIV ntiretroviral therapies. Poster presented at: 66th annual meeting of the American association for the study of liver diseases. Boston, MA, 13–17 Nov 2015.Google Scholar
  25. 25.
    Epclusa. Summary of product characteristics. Available at: Accessed 30 Oct 2017.
  26. 26.
    Soriano V, Fernandez-Montero JV, de Mendoza C, Benitez-Gutierrez L, Pena JM, Arias A, et al. Treatment of hepatitis C with new fixed dose combinations. Expert Opin Pharmacother. 2017;18:1235–42. Scholar
  27. 27.
    Wang T. Poster presented at: EASL 2015, April 22–26, Vienna, Austria.Google Scholar
  28. 28.
    Smolders EJ, de Kanter CT, van Hoek B, Arends JE, Drenth JP, Burger DM. Pharmacokinetics, efficacy, and safety of hepatitis C virus drugs in patients with liver and/or renal impairment. Drug Saf. 2016;39:589–611. Scholar
  29. 29.
    Chen ZW, Li H, Ren H, Hu P. Global prevalence of pre-existing HCV variants resistant to direct-acting antiviral agents (DAAs): mining the GenBank HCV genome data. Sci Rep. 2016;6:20310. Scholar
  30. 30.
    Zeuzem S, Mizokami M, Pianko S, Mangia A, Han KH, Martin R, et al. NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: prevalence and effect on treatment outcome. J Hepatol. 2017;66:910–8. Scholar
  31. 31.
    Pawlotsky JM, Hepatitis C. Virus resistance to direct-acting antiviral drugs in interferon-free regimens. Gastroenterology. 2016;151:70–86. Scholar
  32. 32.
    Sarrazin C, Dvory-Sobol H, Svarovskaia ES, Doehle BP, Pang PS, Chuang SM, et al. Prevalence of resistance-associated substitutions in HCV NS5A, NS5B, or NS3 and outcomes of treatment with ledipasvir and sofosbuvir. Gastroenterology. 2016;151:501–512 e1. Scholar
  33. 33.
    Curry MP, O’Leary JG, Bzowej N, Muir AJ, Korenblat KM, Fenkel JM, et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med. 2015;373:2618–28. Scholar
  34. 34.
    Wyles DL, Luetkemeyer AF. Understanding hepatitis C virus drug resistance: clinical implications for current and future regimens. Top Antivir Med. 2017;25:103–9.PubMedGoogle Scholar
  35. 35.
    Gane E, Shiffman ML, Etzkorn K. Sofosbuvir/velpatasvir in combination with ribavirin for 24 weeks is effective retreatment for patients who failed prior NS5A containing DAA regimens: results of the GS-US-342-1553 study. J Hepatol. 2016;64:S147–8.CrossRefGoogle Scholar
  36. 36.
    AASLD. Recommendations for testing, managing, and treating Hepatitis C. Available at: Accessed 30 Oct 2017.
  37. 37.
    Hull M, Shafran S, Wong A, Tseng A, Giguere P, Barrett L, et al. CIHR Canadian HIV trials network coinfection and concurrent diseases core research group: 2016 Updated Canadian HIV/hepatitis C adult guidelines for management and treatment. Can J Infect Dis Med Microbiol. 2016;2016:4385643. Scholar
  38. 38.
    Hill AM, Saleem J, Heath KA, Simmons B. Effects of sustained virological response (SVR) on the risk of liver transplant, hepatocellular carcinoma, death and re-infection: meta-analysis of 129 studies in 23,309 patients with hepatitis C infection. J Hepatol. 2014;4:218A–9A.Google Scholar
  39. 39.
    Bruno S, Stroffolini T, Colombo M, Bollani S, Benvegnu L, Mazzella G, et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology. 2007;45:579–87. Scholar
  40. 40.
    Cardoso AC, Moucari R, Figueiredo-Mendes C, Ripault MP, Giuily N, Castelnau C, et al. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. J Hepatol. 2010;52:652–7. Scholar
  41. 41.
    Morgan TR, Ghany MG, Kim HY, Snow KK, Shiffman ML, De Santo JL, et al. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology. 2010;52:833–44. Scholar
  42. 42.
    Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck-Ytter Y. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med. 2013;158:329–37. Scholar
  43. 43.
    Miao RY, Zhao HT, Yang HY, Mao YL, Lu X, Zhao Y, et al. Postoperative adjuvant antiviral therapy for hepatitis B/C virus-related hepatocellular carcinoma: a meta-analysis. World J Gastroenterol. 2010;16:2931–42.PubMedPubMedCentralCrossRefGoogle Scholar
  44. 44.
    Singal AK, Freeman DH Jr, Anand BS. Meta-analysis: interferon improves outcomes following ablation or resection of hepatocellular carcinoma. Aliment Pharmacol Ther. 2010;32:851–8. Scholar
  45. 45.
    Zhang W, Song TQ, Zhang T, Wu Q, Kong DL, Li Q, et al. Adjuvant interferon for early or late recurrence of hepatocellular carcinoma and mortality from hepatocellular carcinoma following curative treatment: a meta-analysis with comparison of different types of hepatitis. Mol Clin Oncol. 2014;2:1125–34. Scholar
  46. 46.
    Zhuang L, Zeng X, Yang Z, Meng Z. Effect and safety of interferon for hepatocellular carcinoma: a systematic review and meta-analysis. PLoS One. 2013;8:e61361. Scholar
  47. 47.
    Cabibbo G, Petta S, Barbara M, Missale G, Virdone R, Caturelli E, et al. A meta-analysis of single HCV-untreated arm of studies evaluating outcomes after curative treatments of HCV-related hepatocellular carcinoma. Liver Int. 2017. Scholar
  48. 48.
    Kobayashi M, Suzuki F, Fujiyama S, Kawamura Y, Sezaki H, Hosaka T, et al. Sustained virologic response by direct antiviral agents reduces the incidence of hepatocellular carcinoma in patients with HCV infection. J Med Virol. 2017;89:476–83. Scholar
  49. 49.
    Reig M, Marino Z, Perello C, Inarrairaegui M, Ribeiro A, Lens S, et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol. 2016;65:719–26. Scholar
  50. 50.
    Pompili M, Saviano A, de Matthaeis N, Cucchetti A, Ardito F, Federico B, et al. Long-term effectiveness of resection and radiofrequency ablation for single hepatocellular carcinoma </=3 cm. Results of a multicenter Italian survey. J Hepatol. 2013;59:89–97. Scholar
  51. 51.
    Conti F, Buonfiglioli F, Scuteri A, Crespi C, Bolondi L, Caraceni P, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol. 2016;65:727–33. Scholar
  52. 52. AcsgohcEa. Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: Data from three ANRS cohorts. J Hepatol. 2016;65:734–40. Scholar
  53. 53.
    Reig M. Abstract #PS-031 Presented at: International Liver Congress; April 19–24, 2017; Amsterdam.Google Scholar
  54. 54.
    Majumdar A, Kitson MT, Roberts SK. Systematic review: current concepts and challenges for the direct-acting antiviral era in hepatitis C cirrhosis. Aliment Pharmacol Ther. 2016;43:1276–92. Scholar
  55. 55.
    Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370:1483–93. Scholar
  56. 56.
    Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370:1889–98. Scholar
  57. 57.
    Gane E, Stedman C, Hyland RH, Pang P, Ding X, Symonds W. All-oral sofosbuvir-based 12-week regimens for the treatment of chronic HCV infection: the ELECTRON study. J Hepatol. 2013;58:S6–7.CrossRefGoogle Scholar
  58. 58.
    Bourliere MBJ, de Ledinghen V. Ledipasvir/sofosbuvir fixed dose combination is safe and efficacious in cirrhotic patients who have previously failed protease-inhibitor based triple therapy. Hepatology. 2014;60:1270A.Google Scholar
  59. 59.
    Bourliere M, Sulkowski M, Omata M. An integrated safety and efficacy analysis of > 500 patients with compensated cirrhosis treated with ledipasvir/sofosbuvir with or without ribavirin. Hepatology. 2014;60:239A.Google Scholar
  60. 60.
    Wyles D, Pockros P, Yang C. Retreatment of patients who failed prior sofosbuvir-based regimens with all oral fixed-dose combination ledipasvir/sofosbuvir plus ribavirin for 12 weeks. Hepatology. 2014;60:317A.CrossRefGoogle Scholar
  61. 61.
    Asselah T, Hezode C, Qaqish R. High SVR rates in patients with genotype 4 chronic hepatitis C infection and compensated cirrhosis with ombitasvir/paritaprevir/ritonavir co-administered with ribavirin (AGATE-I). J Hepatol. 2016;64:S827.Google Scholar
  62. 62.
    FDA. FDA Drug Safety Communication: FDA warns of serious liver injury risk with hepatitis C treatments Viekira Pak and Technivie, 2015. Accessed 30 Oct 2017.
  63. 63.
    Feld JJ, Moreno C, Trinh R, Tam E, Bourgeois S, Horsmans Y, et al. Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12 weeks. J Hepatol. 2016;64:301–7. Scholar
  64. 64.
    Pol S, Reddy KR, Baykal T. Interferon-free regimens of ombitasvir and ABT-450/r with or without ribavirin in patients with HCV genotype 4 infection: PEARL-I study results. Hepatology. 2014;60:1129A.Google Scholar
  65. 65.
    Poordad F, Hezode C, Trinh R, Kowdley KV, Zeuzem S, Agarwal K, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med. 2014;370:1973–82. Scholar
  66. 66.
  67. 67.
    Poordad F, Schiff ER, Vierling JM, Landis C, Fontana RJ, Yang R, et al. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatology. 2016;63:1493–505. Scholar
  68. 68.
    Buti M, Gordon SC, Zuckerman E, Lawitz E, Calleja JL, Hofer H, et al. Grazoprevir, elbasvir, and ribavirin for chronic hepatitis C Virus genotype 1 infection after failure of pegylated interferon and ribavirin with an earlier-generation protease inhibitor: final 24-Week results from C-SALVAGE. Clin Infect Dis. 2016;62:32–6. Scholar
  69. 69.
    Forns X, Gordon SC, Zuckerman E, Lawitz E, Calleja JL, Hofer H, et al. Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent. J Hepatol. 2015;63:564–72. Scholar
  70. 70.
    Jacobson I, Lawitz E, Kwo P. An integrated analysis of 402 compensated cirrhotic patients with HCV genotype (GT) 1, 4 or 6 infection treated with grazoprevir/elbasvir. Hepatology. 2015;62:229A.CrossRefGoogle Scholar
  71. 71.
    Kwo P, Gane E, Peng C-Y. Efficacy and safety of grazoprevir/elbasvir ± RBV for 12 weeks with HCV G1 or G4 infection who previously failed Peginterferon/RBV: C-EDGE treatment-experienced trial. J Hepatol. 2015;62:S674.CrossRefGoogle Scholar
  72. 72.
    Lawitz E, Gane E, Pearlman B, Tam E, Ghesquiere W, Guyader D, et al. Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial. Lancet. 2015;385:1075–86. Scholar
  73. 73.
    Feld JJ, Jacobson IM, Hezode C, Asselah T, Ruane PJ, Gruener N, et al. Sofosbuvir and Velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med. 2015;373:2599–607. Scholar
  74. 74.
    Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013;368:1867–77. Scholar
  75. 75.
    Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368:1878–87. Scholar
  76. 76.
    Welzel TM, Nelson DR, Morelli G, Di Bisceglie A, Reddy RK, Kuo A, et al. Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study. Gut. 2016;. Scholar
  77. 77.
    Zeuzem S, Dusheiko GM, Salupere R, Mangia A, Flisiak R, Hyland RH, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med. 2014;370:1993–2001. Scholar
  78. 78.
    Mangia A, Arleo A, Copetti M, Miscio M, Piazzolla V, Santoro R, et al. The combination of daclatasvir and sofosbuvir for curing genotype 2 patients who cannot tolerate ribavirin. Liver Int. 2016;36:971–6. Scholar
  79. 79.
    Foster GR, Pianko S, Brown A, Forton D, Nahass RG, George J, et al. Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection. Gastroenterology. 2015;149:1462–70. Scholar
  80. 80.
    Leroy V, Angus P, Bronowicki JP, Dore GJ, Hezode C, Pianko S, et al. Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: a randomized phase III study (ALLY-3+). Hepatology. 2016;63:1430–41. Scholar
  81. 81.
    Nelson DR, Cooper JN, Lalezari JP, Lawitz E, Pockros PJ, Gitlin N, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology. 2015;61:1127–35. Scholar
  82. 82.
    Welzel TM, Petersen J, Herzer K, Ferenci P, Gschwantler M, Wedemeyer H, et al. Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort. Gut. 2016;65:1861–70. Scholar
  83. 83.
    Soriano V, Labarga P, de Mendoza C, Fernandez-Montero JV, Esposito I, Benitez-Gutierrez L, et al. New hepatitis C therapies for special patient populations. Expert Opin Pharmacother. 2016;17:217–29. Scholar
  84. 84.
    Law WP, Duncombe CJ, Mahanontharit A, Boyd MA, Ruxrungtham K, Lange JM, et al. Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort. AIDS. 2004;18:1169–77.PubMedCrossRefGoogle Scholar
  85. 85.
    Berenguer J, Alvarez-Pellicer J, Carrero A, Von Wichmann MA, Lopez-Aldeguer J, Mallolas J, et al. Clinical effects of viral relapse after interferon plus ribavirin in patients co-infected with human immunodeficiency virus and hepatitis C virus. J Hepatol. 2013;58:1104–12. Scholar
  86. 86.
    Mira JA, Rivero-Juarez A, Lopez-Cortes LF, Giron-Gonzalez JA, Tellez F, de los Santos-Gil I, et al. Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV/hepatitis C virus-coinfected patients with compensated cirrhosis. Clin Infect Dis. 2013;56:1646–53. Scholar
  87. 87.
    Chang S, Dolganiuc A, Szabo G. Toll-like receptors 1 and 6 are involved in TLR2-mediated macrophage activation by hepatitis C virus core and NS3 proteins. J Leukoc Biol. 2007;82:479–87. Scholar
  88. 88.
    Chen M, Wong WW, Law MG, Kiertiburanakul S, Yunihastuti E, Merati TP, et al. Hepatitis B and C Co-infection in HIV patients from the TREAT Asia HIV observational database: analysis of risk factors and survival. PLoS One. 2016;11:e0150512. Scholar
  89. 89.
    Miller MF, Haley C, Koziel MJ, Rowley CF. Impact of hepatitis C virus on immune restoration in HIV-infected patients who start highly active antiretroviral therapy: a meta-analysis. Clin Infect Dis. 2005;41:713–20. Scholar
  90. 90.
    Dazley J, Sison R, Slim J. Long-term consequences of hepatitis c viral clearance on the CD4 (+) T cell lymphocyte course in HIV/HCV coinfected patients. AIDS Res Treat. 2015;2015:687629. Scholar
  91. 91.
    Nunez M, Soriano V, Lopez M, Ballesteros C, Cascajero A, Gonzalez-Lahoz J, et al. Coinfection with hepatitis C virus increases lymphocyte apoptosis in HIV-infected patients. Clin Infect Dis. 2006;43:1209–12. Scholar
  92. 92.
    Feuth T, Arends JE, Fransen JH, Nanlohy NM, van Erpecum KJ, Siersema PD, et al. Complementary role of HCV and HIV in T-cell activation and exhaustion in HIV/HCV coinfection. PLoS One. 2013;8:e59302. Scholar
  93. 93.
    Lundquist CA, Tobiume M, Zhou J, Unutmaz D, Aiken C. Nef-mediated downregulation of CD4 enhances human immunodeficiency virus type 1 replication in primary T lymphocytes. J Virol. 2002;76:4625–33.PubMedPubMedCentralCrossRefGoogle Scholar
  94. 94.
    Tardif MR, Tremblay MJ. Tetraspanin CD81 provides a costimulatory signal resulting in increased human immunodeficiency virus type 1 gene expression in primary CD4+ T lymphocytes through NF-kappaB, NFAT, and AP-1 transduction pathways. J Virol. 2005;79:4316–28. Scholar
  95. 95.
    Cooper CL, Klein MB. HIV/hepatitis C virus coinfection management: changing guidelines and changing paradigms. HIV Med. 2014;15:621–4. Scholar
  96. 96.
    Sarmati L, D’Ettorre G, Parisi SG, Andreoni M. HIV replication at low copy number and its correlation with the HIV reservoir: a clinical perspective. Curr HIV Res. 2015;13:250–7.PubMedPubMedCentralCrossRefGoogle Scholar
  97. 97.
    Zheng L, Taiwo B, Gandhi RT, Hunt PW, Collier AC, Flexner C, et al. Factors associated with CD8+ T-cell activation in HIV-1-infected patients on long-term antiretroviral therapy. J Acquir Immune Defic Syndr. 2014;67:153–60. Scholar
  98. 98.
    Sengupta S, Powell E, Kong L, Blackard JT. Effects of HCV on basal and tat-induced HIV LTR activation. PLoS One. 2013;8:e64956. Scholar
  99. 99.
    Chen TY, Ding EL, Seage Iii GR, Kim AY. Meta-analysis: increased mortality associated with hepatitis C in HIV-infected persons is unrelated to HIV disease progression. Clin Infect Dis. 2009;49:1605–15. Scholar
  100. 100.
    Gonzalez VD, Falconer K, Blom KG, Reichard O, Morn B, Laursen AL, et al. High levels of chronic immune activation in the T-cell compartments of patients coinfected with hepatitis C virus and human immunodeficiency virus type 1 and on highly active antiretroviral therapy are reverted by alpha interferon and ribavirin treatment. J Virol. 2009;83:11407–11. Scholar
  101. 101.
    Hoornenborg E, Achterbergh RCA, van der Loeff MFS, Davidovich U, Hogewoning A, de Vries HJC, et al. MSM starting preexposure prophylaxis are at risk of hepatitis C virus infection. AIDS. 2017;31:1603–10. Scholar
  102. 102.
    Calvaruso V, Ferraro D, Licata A, Bavetta MG, Petta S, Bronte F, et al. HBV reactivation in patients with HCV/HBV cirrhosis on treatment with direct-acting antivirals. J Viral Hepat. 2017;. Scholar
  103. 103.
    Chen G, Wang C, Chen J, Ji D, Wang Y, Wu V, et al. Hepatitis B reactivation in hepatitis B and C coinfected patients treated with antiviral agents: a systematic review and meta-analysis. Hepatology. 2017;66:13–26. Scholar
  104. 104.
    Takayama H, Sato T, Ikeda F, Fujiki S. Reactivation of hepatitis B virus during interferon-free therapy with daclatasvir and asunaprevir in patient with hepatitis B virus/hepatitis C virus co-infection. Hepatol Res. 2016;46:489–91. Scholar
  105. 105.
    Soriano V, Gallego L. Viral hepatitis: treating hepatitis C in injection drug users. Nat Rev Gastroenterol Hepatol. 2013;10:568–9. Scholar
  106. 106.
    Stroffolini T, D’Egidio PF, Aceti A, Filippini P, Puoti M, Leonardi C, et al. Hepatitis C virus infection among drug addicts in Italy. J Med Virol. 2012;84:1608–12. Scholar
  107. 107.
    Babudieri S, Longo B, Sarmati L, Starnini G, Dori L, Suligoi B, et al. Correlates of HIV, HBV, and HCV infections in a prison inmate population: results from a multicentre study in Italy. J Med Virol. 2005;76:311–7. Scholar
  108. 108.
    Sagnelli E, Starnini G, Sagnelli C, Monarca R, Zumbo G, Pontali E, et al. Blood born viral infections, sexually transmitted diseases and latent tuberculosis in italian prisons: a preliminary report of a large multicenter study. Eur Rev Med Pharmacol Sci. 2012;16:2142–6.PubMedGoogle Scholar
  109. 109.
    Almasio PL, Babudieri S, Barbarini G, Brunetto M, Conte D, Dentico P, et al. Recommendations for the prevention, diagnosis, and treatment of chronic hepatitis B and C in special population groups (migrants, intravenous drug users and prison inmates). Dig Liver Dis. 2011;43:589–95. Scholar
  110. 110.
    Marks G, Crepaz N, Senterfitt JW, Janssen RS. Meta-analysis of high-risk sexual behavior in persons aware and unaware they are infected with HIV in the United States: implications for HIV prevention programs. J Acquir Immune Defic Syndr. 2005;39:446–53.PubMedCrossRefGoogle Scholar
  111. 111.
    Dore GJ. C-EDGE CO-STAR: interim results from the 3-year follow-up trial on risk factors and rate of reinfection in patients on opiate agonist therapy previously treated with elbasvir/grazoprevir for 12 weeks. In: Presented at The Liver Meeting, November 11–15, 2016, Boston MA, USA. 2016.Google Scholar
  112. 112.
    Corouge M, Vallet-Pichard A, Pol S. HCV and the kidney. Liver Int. 2016;36:28–33. Scholar
  113. 113.
    Fabrizi F, Aghemo A, Messa P. Hepatitis C treatment in patients with kidney disease. Kidney Int. 2013;84:874–9. Scholar
  114. 114.
    Hsu YC, Ho HJ, Huang YT, Wang HH, Wu MS, Lin JT, et al. Association between antiviral treatment and extrahepatic outcomes in patients with hepatitis C virus infection. Gut. 2015;64:495–503. Scholar
  115. 115.
    Fabrizi F, Messa P. Therapy of hepatitis C by direct-acting anti-virals: the end of HCV in dialysis population? Expert Rev Clin Pharmacol. 2015;8:785–93. Scholar
  116. 116.
    Roth D, Nelson DR, Bruchfeld A, Liapakis A, Silva M, Monsour H Jr, et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet. 2015;386:1537–45. Scholar
  117. 117.
    Pockros PJ, Reddy KR, Mantry PS, Cohen E, Bennett M, Sulkowski MS, et al. Efficacy of direct-acting antiviral combination for patients with hepatitis C virus genotype 1 infection and severe renal impairment or end-stage renal disease. Gastroenterology. 2016;150:1590–8. Scholar
  118. 118.
    Nazario HE, Ndungu M, Modi AA. Sofosbuvir and simeprevir in hepatitis C genotype 1-patients with end-stage renal disease on haemodialysis or GFR < 30 ml/min. Liver Int. 2016;36:798–801. Scholar
  119. 119.
    Singh T, Guirguis J, Anthony S, Rivas J, Hanouneh IA, Alkhouri N. Sofosbuvir-based treatment is safe and effective in patients with chronic hepatitis C infection and end stage renal disease: a case series. Liver Int. 2016;36:802–6. Scholar
  120. 120.
    Colombo M, Aghemo A, Liu H, Zhang J, Dvory-Sobol H, Hyland R, et al. Treatment with ledipasvir-sofosbuvir for 12 or 24 weeks in kidney transplant recipients with chronic hepatitis C virus genotype 1 or 4 infection: a randomized trial. Ann Intern Med. 2017;166:109–17. Scholar
  121. 121.
    Fernandez I, Munoz-Gomez R, Pascasio JM, Baliellas C, Polanco N, Esforzado N, et al. Efficacy and tolerability of interferon-free antiviral therapy in kidney transplant recipients with chronic hepatitis C. J Hepatol. 2017;66:718–23. Scholar
  122. 122.
    Nagao A, Hanabusa H. Brief Report: the impact of ledipasvir/sofosbuvir on HIV-positive and HIV-negative Japanese hemophilia patients with 1, 4, and mixed-genotype HCV. J Acquir Immune Defic Syndr. 2017;74:418–22. Scholar
  123. 123.
    Santagostino E, Pol S, Olveira A, Reesink HW, van Erpecum K, Bogomolov P, et al. Daclatasvir/peginterferon lambda-1a/ribavirin in patients with chronic HCV infection and haemophilia who are treatment naive or prior relapsers to peginterferon alfa-2a/ribavirin. Haemophilia. 2016;22:692–9. Scholar
  124. 124.
    Hezode C, Colombo M, Spengler U, Ben-Ari Z, Strasser S. C-EDGE IBLD: Efficacy and safety of elbasvir/grazoprevir in patients with chronic hepatitis C virus infection and inherited blood disorders. Poster presented at: The international liver congress; EASL-European association for the study of the liver. Barcelona, Spain, 13–17 Apr 2016Google Scholar
  125. 125.
    Cacoub P, Gragnani L, Comarmond C, Zignego AL. Extrahepatic manifestations of chronic hepatitis C virus infection. Dig Liver Dis. 2014;46:S165–73. Scholar
  126. 126.
    Zignego AL, Ferri C, Pileri SA, Caini P, Bianchi FB, Italian Association of the Study of Liver Commission on Extrahepatic Manifestations of HCVi. Extrahepatic manifestations of Hepatitis C Virus infection: a general overview and guidelines for a clinical approach. Dig Liver Dis. 2007;39:2–17. Scholar
  127. 127.
    Zignego AL, Ramos-Casals M, Ferri C, Saadoun D, Arcaini L, Roccatello D, et al. International therapeutic guidelines for patients with HCV-related extrahepatic disorders. A multidisciplinary expert statement. Autoimmun Rev. 2017;16:523–41. Scholar
  128. 128.
    Peveling-Oberhag J, Arcaini L, Bankov K, Zeuzem S, Herrmann E. The anti-lymphoma activity of antiviral therapy in HCV-associated B-cell non-Hodgkin lymphomas: a meta-analysis. J Viral Hepat. 2016;23:536–44. Scholar
  129. 129.
    Zignego AL, Gragnani L, Giannini C, Laffi G. The hepatitis C virus infection as a systemic disease. Intern Emerg Med. 2012;7:S201–8. Scholar
  130. 130.
    Ferri C, Sebastiani M, Giuggioli D, Cazzato M, Longombardo G, Antonelli A, et al. Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients. Semin Arthritis Rheum. 2004;33:355–74.PubMedCrossRefGoogle Scholar
  131. 131.
    Cacoub P, Lidove O, Maisonobe T, Duhaut P, Thibault V, Ghillani P, et al. Interferon-alpha and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis. Arthritis Rheum. 2002;46:3317–26. Scholar
  132. 132.
    Landau DA, Saadoun D, Halfon P, Martinot-Peignoux M, Marcellin P, Fois E, et al. Relapse of hepatitis C virus-associated mixed cryoglobulinemia vasculitis in patients with sustained viral response. Arthritis Rheum. 2008;58:604–11. Scholar
  133. 133.
    Mazzaro C, Zorat F, Comar C, Nascimben F, Bianchini D, Baracetti S, et al. Interferon plus ribavirin in patients with hepatitis C virus positive mixed cryoglobulinemia resistant to interferon. J Rheumatol. 2003;30:1775–81.PubMedGoogle Scholar
  134. 134.
    Montalbano M, Pasulo L, Sonzogni A, Remuzzi G, Colledan M, Strazzabosco M. Treatment with pegylated interferon and ribavirin for hepatitis C virus-associated severe cryoglobulinemia in a liver/kidney transplant recipient. J Clin Gastroenterol. 2007;41:216–20. Scholar
  135. 135.
    Zignego AL, Gragnani L, Visentini M, Casato M. The possible persistence of mixed cryoglobulinemia stigmata in spite of viral eradication: insufficient or too late antiviral treatment? Hepatology. 2016;. Scholar
  136. 136.
    Saadoun D, Resche Rigon M, Pol S, Thibault V, Blanc F, Pialoux G, et al. PegIFNalpha/ribavirin/protease inhibitor combination in severe hepatitis C virus-associated mixed cryoglobulinemia vasculitis. J Hepatol. 2015;62:24–30. Scholar
  137. 137.
    Gragnani L, Fabbrizzi A, Triboli E, Urraro T, Boldrini B, Fognani E, et al. Triple antiviral therapy in hepatitis C virus infection with or without mixed cryoglobulinaemia: a prospective, controlled pilot study. Dig Liver Dis. 2014;46:833–7. Scholar
  138. 138.
    Cornella SL, Stine JG, Kelly V, Caldwell SH, Shah NL. Persistence of mixed cryoglobulinemia despite cure of hepatitis C with new oral antiviral therapy including direct-acting antiviral sofosbuvir: a case series. Postgrad Med. 2015;127:413–7. Scholar
  139. 139.
    Stine JG, Cornella S, Shah NL. Treatment of chronic hepatitis C complicated by mixed cryoglobulinemia with new protease inhibitor, sofosbuvir. Ann Rheum Dis. 2014;73:e64. Scholar
  140. 140.
    Saadoun D, Thibault V, Si Ahmed SN, Alric L, Mallet M, Guillaud C, et al. Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC study. Ann Rheum Dis. 2016;75:1777–82. Scholar
  141. 141.
    Sise ME, Bloom AK, Wisocky J, Lin MV, Gustafson JL, Lundquist AL, et al. Treatment of hepatitis C virus-associated mixed cryoglobulinemia with direct-acting antiviral agents. Hepatology. 2016;63:408–17. Scholar
  142. 142.
    Gragnani L, Visentini M, Fognani E, Urraro T, De Santis A, Petraccia L, et al. Prospective study of guideline-tailored therapy with direct-acting antivirals for hepatitis C virus-associated mixed cryoglobulinemia. Hepatology. 2016;64:1473–82. Scholar
  143. 143.
    Bonacci M, Lens S, Londono MC, Marino Z, Cid MC, Ramos-Casals M, et al. Virologic, clinical, and immune response outcomes of patients with hepatitis C virus-associated cryoglobulinemia treated with direct-acting antivirals. Clin Gastroenterol Hepatol. 2017;15:575–583 e1. Scholar
  144. 144.
    De Vita S, Quartuccio L, Fabris M. Hepatitis C virus infection, mixed cryoglobulinemia and BLyS upregulation: targeting the infectious trigger, the autoimmune response, or both? Autoimmun Rev. 2008;8:95–9. Scholar
  145. 145.
    Petrarca A, Rigacci L, Caini P, Colagrande S, Romagnoli P, Vizzutti F, et al. Safety and efficacy of rituximab in patients with hepatitis C virus-related mixed cryoglobulinemia and severe liver disease. Blood. 2010;116:335–42. Scholar
  146. 146.
    Quartuccio L, Soardo G, Romano G, Zaja F, Scott CA, De Marchi G, et al. Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia: efficacy and safety in the absence of steroids. Rheumatology (Oxford). 2006;45:842–6. Scholar
  147. 147.
    Dreyling M, Thieblemont C, Gallamini A, Arcaini L, Campo E, Hermine O, et al. ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. Ann Oncol. 2013;24:857–77. Scholar
  148. 148.
    European Association for Study of L. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2014;60:392–420. Scholar
  149. 149.
    Torres HA, Mahale P. Most patients with HCV-associated lymphoma present with mild liver disease: a call to revise antiviral treatment prioritization. Liver Int. 2015;35:1661–4. Scholar
  150. 150.
    Zelenetz AD, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, et al. Non-Hodgkin’s lymphomas, version 1.2013. J Natl Compr Canc Netw. 2013;11:257–72 quiz 73.PubMedCrossRefGoogle Scholar
  151. 151.
    Spiegel BM, Younossi ZM, Hays RD, Revicki D, Robbins S, Kanwal F. Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment. Hepatology. 2005;41(4):790–800.PubMedCrossRefGoogle Scholar
  152. 152.
    Loria A, Doyle K, Weinstein AA, Winter P, Escheik C, Price J, et al. Multiple factors predict physical performance in people with chronic liver disease. Am J Phys Med Rehabil. 2014;93:470–6. Scholar
  153. 153.
    Younossi ZM, Stepanova M, Henry L, Gane E, Jacobson IM, Lawitz E, et al. Minimal impact of sofosbuvir and ribavirin on health related quality of life in chronic hepatitis C (CH-C). J Hepatol. 2014;60:741–7. Scholar
  154. 154.
    Younossi ZM, Stepanova M, Marcellin P, Afdhal N, Kowdley KV, Zeuzem S, et al. Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: results from the ION-1, -2, and -3 clinical trials. Hepatology. 2015;61:1798–808. Scholar
  155. 155.
    Younossi ZM, Stepanova M, Feld J, Zeuzem S, Jacobson I, Agarwal K, et al. Sofosbuvir/velpatasvir improves patient-reported outcomes in HCV patients: results from ASTRAL-1 placebo-controlled trial. J Hepatol. 2016;65:33–9. Scholar
  156. 156.
    Gerber L, Estep M, Stepanova M, Escheik C, Weinstein A, Younossi ZM. Effects of Viral Eradication with ledipasvir and sofosbuvir, with or without ribavirin, on measures of fatigue in patients with chronic hepatitis C virus infection. Clin Gastroenterol Hepatol. 2016;14:156–164 e3. Scholar

Copyright information

© Springer-Verlag GmbH Germany 2017

Authors and Affiliations

  • Massimo Andreoni
    • 1
  • Sergio Babudieri
    • 2
  • Savino Bruno
    • 3
  • Massimo Colombo
    • 4
  • Anna L. Zignego
    • 5
  • Vito Di Marco
    • 6
  • Giovanni Di Perri
    • 7
  • Carlo F. Perno
    • 8
  • Massimo Puoti
    • 8
  • Gloria Taliani
    • 9
  • Erica Villa
    • 10
  • Antonio Craxì
    • 11
  1. 1.Infectious Diseases, Polyclinic of Rome Tor VergataRomeItaly
  2. 2.Infectious Diseases Unit, Department of Clinical and Experimental MedicineUniversity of SassariSassariItaly
  3. 3.Humanitas University and Humanitas Research HospitalRozzanoItaly
  4. 4.Humanitas Clinical and Research CenterHumanitas Research HospitalRozzanoItaly
  5. 5.Department of Experimental and Clinical Medicine, Interdepartmental Centre MASVEUniversity of FlorenceFlorenceItaly
  6. 6.Sezione di Gastroenterologia e Epatologia, DiBiMISUniversity of PalermoPalermoItaly
  7. 7.Unit of Infectious Diseases, Department of Medical SciencesAmedeo di Savoia Hospital, University of TurinTurinItaly
  8. 8.Department of Experimental Medicine and SurgeryUniversity of Rome Tor VergataRomeItaly
  9. 9.Infectious and Tropical Diseases UnitUmberto I Hospital-“Sapienza” UniversityRomeItaly
  10. 10.Department of Internal Medicine, Gastroenterology UnitAzienda Ospedaliero-Universitaria Policlinico di ModenaModenaItaly
  11. 11.Gastroenterology and Liver Unit, DiBiMISUniversity of PalermoPalermoItaly

Personalised recommendations